OncoSec Medical Inc (ONCSQ)

[ahab333]

1st Quarter news out

http://finance.yahoo.com/news/oncosec-host-first-quarter-financial-110000502.html

Quarter Financial Results Conference Call on December 8, 2015
PR Newswire OncoSec Medical Incorporated
4 hours ago

????

SAN DIEGO, Nov. 19, 2015 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Company will host its fiscal first quarter 2016 financial results conference call on Tuesday, December 8 at 1:15 PM PT/4:15 PM ET. To listen to the conference call, please dial [phone] (US/Canada) or [phone] (International) and use conference ID number: 83052621. An archived version of the presentation will be available for 90 days on the "Investors" section of OncoSec's website: ir.oncosec.com/events.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer. ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.

Contact
Investor Relations:
Jordyn Kopin
OncoSec Medical Incorporated
855-662-6732
[e-mail]

Media Relations:
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
[e-mail]